News Column

Merck Serono Unveils RebiSmart

June 11, 2014

Merck Serono is launching RebiSmart an updated electronic injection device for the self-administration of Rebif (interferon beta-1a).

RebiSmart will collect and store data and send the information wirelessly to the MSdialog server, the Company noted in its release.

Together with the new RebiSmart, Merck Serono noted that it is also launching MSdialog a web-based software system. It asks patients to complete periodic health report questionnaires. It allows physicians and nurses to monitor through the periodic health report questionnaires.

"Over the years, Merck Serono has continuously worked on enhancing our product profile, taking advantage of the latest medical and technological advances to ultimately meet patient needs," said Belen Garijo, President and CEO of Merck Serono. "With the introduction of MSdialog, we are now leveraging digital technology to offer patients with MS a management system that can help them engage in the treatment of their disease and create a more open dialogue with their healthcare team."

The new RebiSmart and MSdialog will be available in May 2014 in the United Kingdom, Ireland, France, Italy, Switzerland, Austria, Finland, Portugal, Germany, Belgium, Canada, Denmark, Luxembourg, Netherlands and Sweden.

Two strengths of the multidose cartridge - 132 mcg (three doses of 44 mcg) and 66 mcg (three doses of 22 mcg) - were approved by the European Medicines Agency in January 2009.

Merck Serono is the biopharmaceutical division of Merck.

((Comments on this story may be sent to health@closeupmedia.com))


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Health & Beauty Close - Up


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters